Brief Article
Copyright ©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Oct 28, 2009; 15(40): 5067-5073
Published online Oct 28, 2009. doi: 10.3748/wjg.15.5067
Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas
Raffaele Pezzilli, Davide Campana, Antonio M Morselli-Labate, Maria C Fabbri, Emilio Brocchi, Paola Tomassetti
Raffaele Pezzilli, Davide Campana, Antonio M Morselli-Labate, Maria C Fabbri, Emilio Brocchi, Paola Tomassetti, Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna 40138, Italy
Author contributions: Campana D, Fabbri MC, Brocchi E and Tomassetti P administered the questionnaires and clinically followed the patients; Morselli-Labate AM and Pezzilli R analyzed the data and interpreted the results; Pezzilli R and Tomassetti P co-ordinated and collected all the human material; Pezzilli R designed the study and wrote the manuscript.
Correspondence to: Dr. Raffaele Pezzilli, Department of Digestive Diseases and Internal Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, Bologna 40138, Italy. raffaele.pezzilli@aosp.bo.it
Telephone: +39-51-6364148 Fax: +39-51-6364148
Received: July 28, 2009
Revised: August 29, 2009
Accepted: September 5, 2009
Published online: October 28, 2009
Abstract

AIM: To assess the patient-reported outcomes (PROs) of pancreatic neuroendocrine tumor (PNET) patients.

METHODS: Fifty-one consecutive patients (21 male, 30 female, 61.0 ± 10.3 years) with proven PNETs were studied. An SF-12 questionnaire capable of exploring the physical (PCS) and mental (MCS) aspects of daily life was used. Four questionnaires were also used [12 items General Health Questionnaire (GHQ-12) for non-psychotic psychiatric disorders, State Trait Anxiety Inventory (STAI) Y-1 and Y-2 for anxiety and BDI-II for depressive symptoms] to explore the psychological aspects of the disease. Forty-four sex- and age-matched Italian normative subjects were included and evaluated using the SF-12, STAI Y-1 and Y-2 questionnaires.

RESULTS: Seven patients refused to participate to the study; they were clinically similar to the 44 participants who agreed to complete the questionnaires. PNET patients had a PCS score (44.7 ± 11.0) were not significantly different from the norms (46.1 ± 9.9, P = 0.610), whereas the MCS score was significantly lower in patients (42.4 ± 13.0) as compared to the norms (48.2 ± 9.8, P = 0.036). GHQ-12 identified 11 patients (25.0%) as having non-psychotic psychiatric disorders. The STAI scores were similar in the patients and in the normative population. Finally, BDI-II identified eight patients (18.2%) with moderate depression and 9 (20.5%) with mild depression whereas 27 patients (61.4%) had no depression.

CONCLUSION: The PNET patients had a good physical but an impaired mental component of their quality of life; in addition, mild or moderate depressive symptoms are present in about 40% of PNET patients.

Keywords: Endocrine gland neoplasms; Pancreatic neoplasms; Somatostatin; Quality of life; Quality indicators; Health care